Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals Q1 net loss widens to $45.4 million; cash falls to $256.0 million

Negative Impact 3 of 5 earnings Written later

Atea Pharmaceuticals reported a first-quarter 2026 net loss of $45.4 million, or $0.57 per share, up from $34.3 million, or $0.40 per share, a year earlier. Research and development spending rose to $41.1 million, driven by Phase 3 hepatitis C trial costs, and cash, cash equivalents and marketable securities fell to $256.0 million from $301.8 million at December 31, 2025. The filing reports no revenue, and the company said its two hepatitis C Phase 3 topline readouts are expected in mid-2026 and around year-end 2026.

Key points

  • Net loss was $45.4 million ($0.57 per share) for the three months ended March 31, 2026, versus $34.3 million ($0.40 per share) a year earlier.
  • Research and development expenses increased $11.6 million to $41.1 million; general and administrative expenses decreased $2.6 million to $6.9 million.
  • Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million at December 31, 2025.
  • C-BEYOND Phase 3 topline results are expected mid-2026; C-FORWARD topline results are expected around year-end 2026.

The filing

CompanyAtea Pharmaceuticals, Inc. (AVIR)
Form8-K, current report
Filed with the SECMay 12, 2026, 4:17 PM ET
Accession number0001193125-26-219507

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.